NCCN Updates NHL Guidelines
Two recent FDA approvals have prompted the National Comprehensive Cancer Network to update the NCCN Clinical Practice Guidelines in Oncology™ for Non-Hodgkin’s Lymphomas to include ofatumumab (Arzerra™, Glaxo- SmithKline) and romidepsin (Istodax®, Gloucester Pharmaceuticals) as treatment options for selected people with two types of non-Hodgkin’s Lymphomas.
Ofatumumab was added to the NCCN Guidelines as a treatment option for relapsed/refractory disease in people with chronic lymphocytic leukemia. In addition, the updated NCCN Guidelines now include romidepsin as a suggested systemic treatment option for people with mycosis fungoides and Sézary syndrome, two of the most common types of cutaneous T-cell lymphoma.
The most recent version of this and all the NCCN Guidelines are available at NCCN.org.
♦ ♦ ♦ ♦ ♦
This article was printed from copingmag.com and was originally published in Coping® with Cancer magazine, January/February 2010.